Bone Biologics (BBLG) Short-Term Debt issuances (2021)
Bone Biologics (BBLG) reported Short-Term Debt issuances of -$10609.0 for Q1 2021.
Bone Biologics (BBLG) Short-Term Debt issuances (2021) Analysis & Trends
Bone Biologics (BBLG) has 1 years of Short-Term Debt issuances data on file, last reported at -$10609.0 in Q1 2021.
- Short-Term Debt issuances for Q1 2021 came in at -$10609.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was -$10609.0 (changed N/A YoY), and the FY2021 annual result was -$10609.0, down 200.0% from the prior year.
- Short-Term Debt issuances steadied at -$10609.0 in Q1 2021 per BBLG's latest filing.
- Over five years, Short-Term Debt issuances peaked at -$10609.0 in Q1 2021 and troughed at -$10609.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -33,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | -10,609.00 |
| Mar 31, 2021 | -10,609.00 |